Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide: clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

2

Conditions studied

0

US states with sites

1

Countries

Phase breakdown

Phase 3 1

Conditions being studied

Condition	Trials
Advanced Gastroenteropancreatic Neuroendocrine Tumor	1
Pancreatic cancer	1

Recruiting trials involving Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations

Common questions

How many recruiting trials involve Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide?

1 recruiting trial across 2 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.